Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
PLRX Stock Chart & Stats
$1.80
-$0.35(-2.64%)
At close: 4:00 PM EST
$1.80
-$0.35(-2.64%)
Day’s Range― - ―
52-Week Range$1.10 - $15.85
Previous CloseN/A
Volume34.91K
Average Volume (3M)581.13K
Market Cap
$98.83M
Enterprise Value-$131.29M
Total Cash (Recent Filing)$241.80M
Total Debt (Recent Filing)$59.86M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 03, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding61,388,153
10 Day Avg. Volume902,150
30 Day Avg. Volume581,135
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.62
Price to Sales (P/S)0.00
P/FCF Ratio-5.00
Enterprise Value/Market Cap-1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit146.69
Enterprise Value/Ebitda0.78
Forecast
1Y Price Target
$3.00Price Target Upside66.67% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPatient enrollment of the open-label Phase I study for PLN-101095 (αvβ8 & αvβ1 dual inhibitor) has been completed.
Clinical OutcomesThe study reported interim results from the first three cohorts, demonstrating an antitumor activity of PLN-101095+pembrolizumab combination therapy, with three partial responses observed in cohort three.
Financial PositionPLRX reported a cash position of $264M which should take them through 2028.
Bears Say
Pipeline ChallengesMaintain Hold on a limited development pipeline and lack of upside.
Program DiscontinuationThe recent discontinuation of the phase 2b BEACON-IPF study is seen as a fundamental setback for bexotegrast.
Strategic UncertaintyThere is no clear near-term inflection point and any strategic business development update may be met with investor skepticism.
Pliant Therapeutics News
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $1.10 and its highest was $15.85 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is $98.83M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 109 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.524 by $0.094.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.42.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,388,153 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.524. Following the earnings report the stock price went up 4.575%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in PLRX
Pliant Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (66.67% Upside)
$3.00 (66.67% Upside)
Hedge Fund Trend
Decreased
By 499.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.21%
12-Months-Change
Fundamentals
Return on Equity
-64.27%
Trailing 12-Months
Asset Growth
-38.02%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
PLRX Stock 12 Month Forecast
Average Price Target
$3.00
▲(66.67% Upside)
Technical Analysis
Ownership Overview
3.65% Insiders
6.75% Mutual Funds
0.24% Other Institutional Investors
84.32% Public Companies and
Individual Investors